Evaluation of the immune potentiating effect of the NAcGM3/VSSP/Montanide ISA 51 formulation in HIV patients, phase II.

Trial Profile

Evaluation of the immune potentiating effect of the NAcGM3/VSSP/Montanide ISA 51 formulation in HIV patients, phase II.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs N-acetyl GM3 vaccine (Primary) ; Montanide ISA-51
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 23 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top